Global Dysmenorrhea Treatment Information, By Type (Primary, Secondary), By Treatment (Non-Steroidal Anti-Inflammatory Drugs (NsAIDs), Hormonal, Combined Oral Contraceptive), By End User (Hospitals And Clinics, Diagnostic Centers, Pharmaceutical Companies And Others) - Forecast To 2023

Market Scenario:

Dysmenorrhea is a medical term for painful menstruation. Many women suffer from pain in lower abdomen during menstruation. This is due to low hemoglobin levels in women's and lack of nutritious diet taken by women. Women nowadays have to cope up with both physical and mental stress due to personal issues and other work related problems. Most of them consult a physician for various reproductive disorders. The demand for the treatment of dysmenorrhea is increasing due to increasing reproductive disorders in women, irregular menstrual cycle, increase in lifestyle disorders and addiction to smoking deteriorating their physical and mental health. Lack of awareness about the treatment regarding various reproductive disorders and use of medications for their treatment also contribute for the growth of this market. Women in developed countries face many health issues due to lifestyle changes and many develop diseases related to reproductive health which favors the growth of this market in developed countries across the globe. Risk of developing serious disorders, if the disease remains untreated, would increase in demand of treatment in hospitals. Global market of Dysmenorrhea Treatment is expected to reach US$ 8.40 billion in 2023 from US$ 5.68 billion in 2016 with a CAGR of approximately 12.28% during the forecast period 2017-2023.

Study Objectives:

Main objective of this research is to provide information about the products, their application and their end users

- To provide detailed analysis of the market structure along with forecast for the next six years of the various segments and sub-segments of the Dysmenorrhea Treatment market.
- To provide insights about factors affecting the market growth.
- To analyze the dysmenorrhea treatment market based on various factors- Price Analysis, Supply Chain Analysis, Porters Five Force Analysis etc.
- To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific and Middle East and Africa.
- To provide country level analysis of the market with respect to the current market size and future prospective.
- To provide country level analysis of the market for segments by type, by treatment, by end users and its sub-segments.
To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Dysmenorrhea Treatment market.

**Intended Audience**

- Dysmenorrhea medicine suppliers
- Dysmenorrhea medicine manufacturers
- Research and Development (R&D) Companies
- Medical Research Laboratories
- Diagnostic centers
- Academic Medical Institutes and Universities

**Figure 1: Research methodology for Dysmenorrhea Treatment market:**

**Segmentation:**

Global Dysmenorrhea Treatment market has been segmented on the basis of Type which includes Primary Dysmenorrhea and Secondary Dysmenorrhea. Secondary Dysmenorrhea has sub-segments namely Endometriosis, Adenomyosis, Uterine myomas, Endometrial polyps, Cervical stenosis, Obstructive malformations of genital tract. On the basis of treatment the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), hormonal, and combined oral contraceptive. End users are hospitals and clinics, diagnostic centers, pharmaceutical companies and others.

**Figure 2: Market Synopsis of Dysmenorrhea Treatment Market by end user, 2016 (%):**
Regional Analysis of Dysmenorrhea Treatment Market:

Globally, Dysmenorrhea Treatment market is spread across four regions America, Europe, Asia-Pacific and Middle East and Africa. North America is the largest market for dysmenorrhea. The factor contributing for the growth of this market is an increase in problems with reproductive healthy among women and changing lifestyle. Asia Pacific is expected to be the fastest growing market for dysmenorrhea treatment. India is expected to be the emerging and fastest growing region. The market shows steady growth in Middle East and Africa.

Key Players for Dysmenorrhea Treatment Market:

Some of the key players in this market are: Novartis AG (Switzerland), Merck, Inc. (U.S), Bayer Schering Pharma AG (Germany), Abbott Healthcare(U.S), Pfizer, Inc.(U.S). Other players include F. Hoffmann-La Roche Ltd (U.S), Sanofi (U.S), Taj Pharmaceuticals, Ltd (India).

The report for Dysmenorrhea Treatment market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.
4.1.1 Increase in number of women with period pain
4.2 Restraints
4.2.1 Lack of awareness about reproductive health in women

5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining power of suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
5.2 Supply Chain Analysis

6. Global Dysmenorrhea Treatment market by type
6.1 Primary Dysmenorrhea
6.2 Secondary Dysmenorrhea
6.2.1 Endometriosis
6.2.2 Adenomyosis
6.2.3 Uterine myomas
6.2.4 Endometrial polyps
6.2.5 Cervical stenosis
6.2.6 Obstructive malformations of genital tract

7. Global Dysmenorrhea Treatment market by treatment
7.1 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
7.2 Hormonal Treatment
7.3 Combined Oral Contraceptive

8. Global Dysmenorrhea Treatment market by end user
8.1 Hospitals and clinics
8.2 Diagnostic centres
8.3 Pharmaceutical companies
8.4 Others

9. Global Dysmenorrhea Treatment market by region
9.1 Introduction
9.2 Americas
9.2.1 North America
9.2.1.1 US
9.2.1.2 Canada
9.2.2 South America
9.3 Europe
9.3.1 Western Europe
9.3.1.1 Germany
9.3.1.2 France
9.3.1.3 Italy
9.3.1.4 Spain
9.3.1.5 UK
9.3.1.6 Rest of Western Europe
9.3.2 Eastern Europe
9.4 Asia-Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Republic of Korea
9.4.5 Australia
9.4.6 Rest of Asia-Pacific
9.5 Middle East and Africa
9.5.1 United Arab Emirates
9.5.2 Saudi Arabia
9.5.4 Rest of Middle East and Africa

10 Competitive Landscape
10.1 Cost of dysmenorrhea treatment
10.2 Production Capacity of Major Players

11 Company Profile
11.1 Novartis AG
11.1.1 Overview
11.1.2 Product/Business Segment Overview
11.1.3 Financial Updates
11.1.4 Key Developments
11.2 Medtronic plc.
11.2.1 Overview
11.2.2 Product/Business Segment Overview
11.2.3 Financial Updates
11.2.4 Key Developments
11.3 Bayer Schering Pharma AG
11.3.1 Overview
11.3.2 Product/Business Segment Overview
11.3.3 Financial Updates
11.4 Abbott Healthcare
11.4.1 Overview
11.4.2 Product/Business Segment Overview
11.4.3 Financial Updates
11.4.4 Key Development
11.5 Pfizer, Inc
11.5.1 Overview
11.5.2 Product/Business Segment Overview
11.5.3 Financial Updates
11.5.4 Key Developments
11.6 F. Hoffmann-La Roche Ltd
11.6.1 Overview
11.6.2 Product/Business Segment Overview
11.6.3 Financial Updates
11.6.4 Key Developments
11.7 Others

12 Conclusion
12.1 Key Findings
12.1.1 From CEO’s Viewpoint
12.1.2 Unmet Needs of the Market
12.2 Key Companies to Watch
12.3 Prediction of Insomnia Industry

13 Appendix